Table 4.
Integrated discrimination improvement and net reclassification improvement by adding CKD273 to the basic model including covariables
| Biomarkers (threshold) | Integrated discrimination improvement |
Net reclassification Improvement |
||||
|---|---|---|---|---|---|---|
| IDI (%) | CI (%) | P value | NRI (%) | CI (%) | P value | |
| UAE continuous | 0.69 | –0.04 to 1.41 | 0.065 | 20.1 | 9.14 to 31.1 | 0.0003 |
| UAE (20 μg/min) | 0.50 | –0.17 to 1.18 | 0.14 | 8.22 | –1.16 to 17.6 | 0.086 |
| CKD273 continuous | 0.86 | 0.04 to 1.68 | 0.039 | 25.8 | 14.9 to 36.8 | <0.0001 |
| CKD273 (0.154) | 0.34 | –0.21 to 0.88 | 0.23 | 23.3 | 14.5 to 32.1 | <0.0001 |
| CKD273 (0.343) | 0.57 | –0.08 to 1.23 | 0.085 | 17.9 | 10.8 to 25.1 | <0.0001 |
CI, confidence interval; CKD273, urinary proteomic biomarker; IDI, integrated discrimination improvement; NRI, net reclassification improvement; UAE, urinary albumin excretion rate.
The basic reference models were stratified by study center and included sex, age, mean arterial pressure, estimated glomerular filtration rate, and prevalence of diabetes at baseline as covariables. The integrated discrimination improvement is the difference between the discrimination slopes of basic models and basic models extended with CKD273. The discrimination slope is the difference in predicted probabilities (%) between patients and control subjects. Control subjects are participants without incident chronic kidney disease. The net reclassification improvement is the sum of the percentages of subjects reclassified correctly in the groups of cases and control subjects. All estimates are provided with 95% confidence intervals.